SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

SpringWorks Therapeutics (Nasdaq: SWTX) announced management's participation in a fireside chat at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 12:50 p.m. ET. The event will focus on the company's mission to develop life-changing medicines for patients with severe rare diseases and cancer. Interested parties can access the live webcast through the Investors & Media section on their website, with a replay available afterward. SpringWorks is known for its targeted oncology pipeline and innovative partnerships aimed at advancing clinical development in rare and genetically defined cancers.

STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Cowen 43^rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

SpringWorks Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com

FAQ

When is the SpringWorks Therapeutics fireside chat scheduled?

The SpringWorks Therapeutics fireside chat is scheduled for March 7, 2023, at 12:50 p.m. ET.

How can I access the SpringWorks Therapeutics webcast?

You can access the SpringWorks Therapeutics webcast through the Events & Presentations page in the Investors & Media section of their website.

What is the focus of SpringWorks Therapeutics' pipeline?

SpringWorks Therapeutics focuses on developing targeted oncology treatments for patients with rare diseases and cancers.

What are the key products in SpringWorks Therapeutics' pipeline?

SpringWorks has two lead product candidates currently in late-stage clinical trials targeting rare tumor types.

What is the stock symbol for SpringWorks Therapeutics?

The stock symbol for SpringWorks Therapeutics is SWTX.